Popular Articles
Teeth Whitening Products

Chicago Public Schools To Launch Education, Treatment Program To Curb Chlamydia, Gonorrhea
The Chicago Public Schools system this year will launch a pilot program to provide students in grades 11 and 12 with voluntary education, testing and treatment for chlamydia and gonorrhea, the Chicago Sun-Times reports. The Chicago Department of Public Health will administer the program at six Cook County, Ill., schools at no cost to the school system.According to the Sun-Times, Centers for Disease Control and Prevention data from 2007 -- the most recent year available -- showed that Cook County had the second-highest number of reported chlamydia cases in the U.S. at 583 cases per 100,000 people, or 30,881 total cases. In addition, the county rated first in the nation for reported gonorrhea cases at 233 per 100,000 people, or 12,338 total cases.Christopher Brown, assistant commissioner of the health department, said, "It"s a very large problem with teens and adolescents in Chicago, and it"s very, very important that they get the information about these sexually transmitted infections." He added, "Our goal is to get the information out to teens -- about how they"re transmitted in particular -- and also that there"s treatment available."The six schools have yet to be selected, and they may opt not to participate if chosen, the Sun-Times reports. To qualify, schools must have their own health centers. Monique Bond, a spokesperson for CPS, said that the health centers will administer the testing and provide treatment to students with the STIs (Ihejirika, Chicago Sun-Times, 6/26).
generic viagra online
National Cancer Institute Research Identifies Unique Mechanism Of Brostallicin's Anti-Tumor Effectiveness
Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced that researchers from the Laboratory of Molecular Pharmacology at the National Cancer Institute presented new preclinical research identifying unique anti-tumor mechanisms of brostallicin that sets this agent apart from other currently used chemotherapy agents. CTI acquired worldwide rights to brostallicin when it acquired privately-held Systems Medicine LLC in 2007. Published in the journal Molecular Cancer Therapy (Mol Cancer Ther 2009;8(7) July 2009; 1985-94), the researchers utilized preclinical studies to provide clues into tumor susceptibility mechanisms for brostallicin, a synthetic DNA minor grove binder, and to identify differences between brostallicin and trabectedin (Yondelis(R); ET-743), which is a natural marine product approved in Europe. Unlike other chemotherapy agents, including trabectedin, the NCI research indicates that the tumor cell DNA damaging effects of brostallicin are enhanced by high tumor glutathione levels, a hallmark of drug-resistant tumors. Brostallicin was shown to affect DNA in both dividing and quiescent cells. Its actions can be followed by induction of a specific DNA binding protein foci that can be detected in circulating blood cells. Importantly, brostallicin was active in a trabectedin-resistant cell line.
News of the day
RCN Responds To Report On NHS Pay Modernisation In England
Responding to the publication of the Public Accounts Committee report, NHS pay modernisation in England: Agenda for Change, Dr Peter Carter, RCN Chief Executive & General Secretary, said:
Nutrition

Senate Bill To Protect Patients' Healthcare By Amending Medicare Coverage

The U.S. Senate has introduced a bill, S. 1221, "The Medicare Prompt Pay Correction Act," a companion bill to H.R. 1392, which was introduced in the U.S. House of Representatives and currently has 45 co-sponsors. The Senate bill was introduced by Senators Arlen Specter (D-PA) and Pat Roberts (R-KS). The bill is a step forward in addressing problems with Medicare reimbursement for cancer drugs and in alleviating a national problem affecting the delivery of cancer care treatment to patients, almost all of whom are treated in community oncology clinics close to their homes. "Community cancer clinics play a critical role in our nation"s fight against cancer, especially in rural areas where families do not have access to larger centers," said U.S. Senator Arlen Specter (D-PA). "I am pleased to introduce this legislation which will help ensure access for Medicare beneficiaries" to potentially life-saving cancer treatments." This bill will amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under Part B of the Medicare Program. It excludes customary prompt pay discounts extended to wholesalers from the manufacturer"s Average Sales Price (ASP). These discounts artificially reduce Medicare Part B drug reimbursement rates for community oncology clinics, jeopardizing the viability of these providers and thus endangering patient access to affordable, quality cancer care in their communities. Excluding distributor prompt pay discounts from the ASP methodology is consistent with existing policy and will create greater uniformity among federal healthcare programs. The Medicaid Average Manufacturer Price (AMP) methodology already excludes these terms. This legislation is an effort to improve the delivery of cancer care treatment to patients. Cancer care must be understood as different from general healthcare in that it is catastrophic in its threat to life, its potency of treatment and its cost. The cancer care delivery system is now in first-stage crisis because Medicare has substantially cut payment for cancer drugs and essential services. Almost all Americans are currently treated in community cancer clinics, many of which have had to cut staff and close satellite facilities. Patients with insufficient or no insurance, especially seniors and the swelling ranks of the unemployed, are increasingly being sent elsewhere for treatment and some patients are actually foregoing treatment. "Especially during these tough economic times, millions of patients should not have to opt-out of quality cancer treatment because they can"t afford it," said U.S. Senator Pat Roberts (R-KS). The problem not only centers on payments for cancer drugs, but also on essential services provided to cancer patients, such as treatment planning, which are not reimbursed by Medicare. The Community Oncology Alliance (COA) has aggressively advocated for the prompt pay solution. "We appreciate the leadership of Senator Specter, who has long supported cancer care funding issues, and Senator Roberts for cosponsoring this important legislation," said Patrick Cobb, M.D., president of the Community Oncology Alliance (COA) and managing partner of Hematology-Oncology Centers of the Northern Rockies in Billings, Montana. "This bipartisan bill is a welcomed and needed first step in supporting community cancer clinics," he continued. "The passage of these congressional bills will enable community oncology clinics to continue providing patients with cancer care treatments currently not properly reimbursed by Medicare." About Community Oncology Alliance (COA) COA is a non-profit organization dedicated solely to community oncology. COA was founded by community oncology to advocate for patients and providers in the community oncology setting, where 84 percent of Americans with cancer are treated. In only six years of existence, COA has mobilized community oncology to become more politically active, and increased awareness on Capitol Hill about the community cancer care delivery system. Additionally, COA has brought together community oncology practices from across the country to share information in order to enhance the effectiveness and efficiency of the cancer care they provide to their patients. Currently, COA is working with the Congress in proving proactive solutions designed to protect the viability of the nation"s cancer care delivery system and patients" access to quality, affordable cancer care. The cancer death rate in the U.S. has declined due to earlier detection, the quality of treatment, and the accessibility of cancer care. However, according to the American Cancer Society, men still have an approximately one in two lifetime risk of developing cancer, with a risk of one in three for women. Community Oncology Alliance


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):